Pretomanid, Dovprela (previously pretomanid fgk)(pretomanid)
Dovprela, Pretomanid (pretomanid) is a small molecule pharmaceutical. Pretomanid was first approved as Pretomanid on 2019-08-14. It is used to treat extensively drug-resistant tuberculosis in the USA. It has been approved in Europe to treat multidrug-resistant tuberculosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Pretomanid
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pretomanid | New Drug Application | 2024-11-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| extensively drug-resistant tuberculosis | — | D054908 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PRETOMANID, PRETOMANID, MYLAN IRELAND LTD | |||
| 2029-08-14 | GAIN | ||
| 2026-08-14 | ODE-253 | ||
| 2024-08-14 | NCE | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 10 | 17 | 9 | 2 | 2 | 35 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | 1 | 5 | 7 | 1 | 1 | 11 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 16 | 9 | — | — | 21 |
| Extensively drug-resistant tuberculosis | D054908 | — | — | — | 3 | 4 | — | — | 4 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 3 | 2 | — | — | 4 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pretomanid |
| INN | pretomanid |
| Description | Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | mycolic acid inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(OC(F)(F)F)cc1)C2 |
Identifiers
| PDB | — |
| CAS-ID | 187235-37-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL227875 |
| ChEBI ID | — |
| PubChem CID | 456199 |
| DrugBank | DB05154 |
| UNII ID | 2XOI31YC4N (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,377 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
323 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use